Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1970 Nov;20(5):770-4.
doi: 10.1128/am.20.5.770-774.1970.

Quantitation of the antigenicity and immunogenicity of purified foot-and-mouth disease virus vaccine for swine and steers

Quantitation of the antigenicity and immunogenicity of purified foot-and-mouth disease virus vaccine for swine and steers

D O Morgan et al. Appl Microbiol. 1970 Nov.

Abstract

The antigenicity and immunogenicity of a purified preparation of foot-and-mouth disease virus [type A(12), strain 119 (FMDV A-119)] inactivated with 6.0 mmN-acetylethylenimine at 37 C were compared in swine and steers. Three antigen doses were tested, 640, 160, and 40 ng. In accordance with findings for guinea pigs, as previously determined by dose-response curves, as little as fourfold changes in antigen in the region of the minimum effective dose produced marked differences in the serological and immune responses of swine. The minimum effective dose of antigen for antibody formation in swine and guinea pigs, as determined by mouse median protective dose (PD(50)) values, was 160 ng. The minimum immunogenic dose for swine was also 160 ng. The vaccinated swine were challenged with either FMDV A-119 or with heterologous subtype A(24) strain Cruzeiro or type A strain A-CANEFA-1. Those immunized with 640 ng of antigen were about equally immune to the three challenge viruses; most swine having a mouse PD(50) value of 2.0 or greater were immune regardless of which strain was used for challenge. In steers, the smallest dose tested, 40 ng, was satisfactory in eliciting circulating antibodies and immunity. Physical and biological tests indicated that the antigen used in the vaccine is stable for at least 9 months at 4 C.

PubMed Disclaimer

References

    1. Can J Comp Med Vet Sci. 1963 Aug;27(8):193-7 - PubMed
    1. J Hyg (Lond). 1952 Jun;50(2):182-94 - PubMed
    1. Zentralbl Veterinarmed B. 1969 Aug 6;16(6):488-511 - PubMed
    1. Appl Microbiol. 1969 Mar;17(3):441-5 - PubMed
    1. Virology. 1962 Feb;16:147-51 - PubMed

LinkOut - more resources